Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment.
Ylisaukko-Oja T, Af Björkesten CG, Eberl A, Nuutinen H, Jussila A, Molander P, Koskela R, Blomster T, Pajala M, Ilus T, Haiko P, Kovac B, Silvola S, Smith S, Jokelainen J, Sipponen T. Ylisaukko-Oja T, et al. Among authors: blomster t. Heliyon. 2024 Jun 4;10(12):e32432. doi: 10.1016/j.heliyon.2024.e32432. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38975101 Free PMC article.
Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T. Molander P, et al. Among authors: blomster t. Inflamm Bowel Dis. 2014 Jun;20(6):1021-8. doi: 10.1097/MIB.0000000000000052. Inflamm Bowel Dis. 2014. PMID: 24798636 Clinical Trial.
Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T. Molander P, et al. Among authors: blomster t. J Crohns Colitis. 2015 Jan;9(1):33-40. doi: 10.1016/j.crohns.2014.06.012. J Crohns Colitis. 2015. PMID: 25052347 Clinical Trial.
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. Ylisaukko-Oja T, et al. Among authors: blomster t. Scand J Gastroenterol. 2018 Feb;53(2):158-167. doi: 10.1080/00365521.2017.1416160. Epub 2017 Dec 19. Scand J Gastroenterol. 2018. PMID: 29258369
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T. Ylisaukko-Oja T, et al. Among authors: blomster t. Biologicals. 2019 Mar;58:50-56. doi: 10.1016/j.biologicals.2019.01.007. Epub 2019 Feb 10. Biologicals. 2019. PMID: 30755369 Clinical Trial.
54 results